Login to Your Account



Biosimilar Pioneers Play Their Strategy Cards Close to Vest


Wednesday, January 16, 2013
With an established reputation for its generic drugs, Mumbai, India-based Lupin Ltd. has expanded into biosimilars in its quest to become a global biopharma powerhouse. But like the foggy view from the 32nd-floor penthouse location of the Asia track at the J.P. Morgan Healthcare Conference last week, the firm's chief financial officer provided limited insight into the company's biosimilars strategy despite audience questions.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription